BioSpace News Archive

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced participation in the 2022 PDA Universe of Pre-Filled Syringes and Injection Devices Conference to showcase its leadership and expertise on industry challenges and trends in packaging and containment.

IDEAYA Biosciences, Inc. announced clinical program updates for IDE397, an investigational, potential best-in-class, small molecule MAT2A inhibitor being evaluated in an ongoing Phase 1/2 clinical trial.

The Longevity Science Foundation, a global nonprofit organization providing research funding to establish a longer and healthier human lifespan, has recently expanded by launching operations in the United States and appointing a new President & CEO, Lisa E. Ireland.

Empyrean Neuroscience, Inc. announced that it has launched with a $22 million Series A financing and a genetic engineering platform to advance a pipeline of neuroactive compounds targeting disorders of the central nervous system.

Johnson & Johnson announced results for third-quarter 2022. “Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses,” said Joaquin Duato, Chief Executive Officer.

Genmab A/S announced that worldwide net trade sales of DARZALEX®,including sales of the subcutaneous product,as reported by Johnson & Johnson were USD 2,052 million in the third quarter of 2022.

Emergent BioSolutions Inc. will host a conference call on Tuesday, November 8, 2022, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2022, recent business developments, and financial outlook for full year 2022.

ViewRay, Inc. announced the launch of a phase III randomized controlled trial titled “Locally Advanced Pancreatic cancer treated with ABLAtivE stereotactic MRI-guided adaptive radiation therapy” – also known as LAP-ABLATE.

NuGen Medical Devices Inc., a leader in needle-free drug delivery, is pleased to announce that it has received confirmation of its official certification for its wholly owned subsidiary European Pharma Group B.V.

Zomedica Corp. announced that Larry Heaton, Zomedica’s Chief Executive Officer, is scheduled to provide a company overview and its prospects for growth at the LD Micro Main Event XV Conference on October 25, 2022 at the Luxe Sunset Boulevard Hotelin Bel Air, California.